ArticleNeoplasia (New York, N.Y.)2025

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat.

Tamara Zenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.